Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 10/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4591950 | 0.88 | F10 (0.46) | F10SYKKLKB1MAPK1 | |
| SCHEMBL6524527 | 0.84 | CASP1 (0.40) | F10MEN1KMT2AMAPK1LMNA | |
| SCHEMBL3343070 | 0.82 | ALDH1A1 (0.38) | MEN1KMT2AMAPK1SMN1; SMN2LMNA | |
| SCHEMBL3342474 | 0.81 | POLB (0.47) | MEN1KMT2AMAPK1SMN1; SMN2LMNA | |
| SCHEMBL3342210 | 0.81 | ALDH1A1 (0.49) | MEN1KMT2AMAPK1LMNAALDH1A1 | |
| SCHEMBL1030894 | 0.79 | F10 (0.47) | F10SYKKLKB1 | |
| SCHEMBL13907449 | 0.79 | KMT2A (0.53) | F10MEN1KMT2AP2RX7MAPK1 | |
| SCHEMBL3340313 | 0.78 | CRBN (0.46) | MEN1KMT2AP2RX7MAPK1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4999282 | 0.78 | F10 (0.47) | F10SYKKLKB1 | |
| SCHEMBL6522042 | 0.78 | MAPT (0.43) | F10MEN1KMT2AP2RX7KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8435990-B2 | Dihydropyrimidone amides as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2013-05-07 | — | — | US | disclosed |
| US-20110028502-A1 | DIHYDROPYRIMIDONE AMIDES AS P2X7 MODULATORS | BROTHERTON-PLEISS CHRISTINE E | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028502-A1 | DIHYDROPYRIMIDONE AMIDES AS P2X7 MODULATORS | P2RY1, P2RX7, P2RX3 | F10 2418/4885MEN1 2873/4885KMT2A 3668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.